Guidelines on Germline Testing for Urologic Tumor Syndromes.
Publication/Presentation Date
5-1-2022
Abstract
In the expanding precision medicine landscape, along with improvements in and the availability of testing, the use of genetics in the evaluation and treatment of patients has increased significantly. Multiple urologic cancers in different organ systems associated with an inherited gene mutation have been described. As these mutations can impact screening and treatment decisions for patients and their families, it is important for providers to be familiar with the current guidelines for germline testing. Here we summarize the current guidelines regarding germline testing for patients with suspected urologic tumor syndromes. PATIENT SUMMARY: Several cancers of the genitourinary tract can be associated with inherited genetic mutations. Knowledge of when to test for these mutations has implications for both treatment and screening of patients and their family members at risk of genitourinary cancers.
Volume
8
Issue
3
First Page
670
Last Page
673
ISSN
2405-4569
Published In/Presented At
Gomella, P. T., Mark, J. R., Giri, V. N., Kelly, W. K., & Gomella, L. G. (2022). Guidelines on Germline Testing for Urologic Tumor Syndromes. European urology focus, 8(3), 670–673. https://doi.org/10.1016/j.euf.2022.06.010
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
35803854
Department(s)
Administration and Leadership
Document Type
Article